-
1.发明申请CORE AND SURFACE MODIFICATION OF MESOPOROUS SILICA NANOPARTICLES TO ACHIEVE CELL SPECIFIC TARGETING IN VIVO 审中-公开多孔二氧化硅纳米粒子在体细胞中实现细胞特异性靶向的核心和表面修饰
公开(公告)号：WO2015042268A1
公开(公告)日：2015-03-26
申请号：PCT/US2014/056312
申请日：2014-09-18
Applicant: STC.UNM , SANDIA CORPORATION
Inventor： BRINKER, Jeffrey, C. , TOWNSON, Jason , LIN, Yu-Shen , DURFEE, Paul, N.
CPC classification number: A61K47/48215 , A61K9/0019 , A61K9/1271 , A61K9/5115 , A61K9/5146 , A61K47/02 , A61K47/59 , A61K47/60 , A61K47/6923 , A61K47/6929
Abstract: In one aspect, the invention provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit single cell binding specificity to the substantial exclusion of non-targeted cells. For example, MSNPs and protocells of the invention may be used to target specific delivery of therapeutic agents to cancer cells or to specific blood vessel types (e.g. in the arterial, venous and/or capillary vessels or any combination of vessels). Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.
Abstract translation: 一方面，本发明提供介孔二氧化硅纳米颗粒（MSNP），MSNP的单分散群体和相关的原细胞，其显示出对非靶向细胞的实质排除的单细胞结合特异性。 例如，本发明的MSNPs和原细胞可用于靶向治疗剂对癌细胞或特定血管类型（例如在动脉，静脉和/或毛细管血管或血管的任何组合中）的特异性递送。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。
-
2.发明公开CORE AND SURFACE MODIFICATION OF MESOPOROUS SILICA NANOPARTICLES TO ACHIEVE CELL SPECIFIC TARGETING IN VIVO 审中-公开KERN- UNDOBERFLÄCHENMODIFIKATIONMESOPORÖSERSILICIUMDIOXIDNANOTEILCHENFÜRZELLSPEZIFISCHES IN VIVO-TARGETING
公开(公告)号：EP3046547A1
公开(公告)日：2016-07-27
申请号：EP14846653.5
申请日：2014-09-18
Applicant: STC.UNM , SANDIA CORPORATION
Inventor： BRINKER, Jeffrey, C. , TOWNSON, Jason , LIN, Yu-Shen , DURFEE, Paul, N.
CPC classification number: A61K47/48215 , A61K9/0019 , A61K9/1271 , A61K9/5115 , A61K9/5146 , A61K47/02 , A61K47/59 , A61K47/60 , A61K47/6923 , A61K47/6929
Abstract: In one aspect, the invention provides mesoporous silica nanoparticles (MSNPs), monodisperse populations of MSNPs and related protocells which exhibit single cell binding specificity to the substantial exclusion of non-targeted cells. For example, MSNPs and protocells of the invention may be used to target specific delivery of therapeutic agents to cancer cells or to specific blood vessel types (e.g. in the arterial, venous and/or capillary vessels or any combination of vessels). Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.
Abstract translation: 一方面，本发明提供介孔二氧化硅纳米颗粒（MSNP），MSNP的单分散群体和相关的原细胞，其显示出对非靶向细胞的实质排除的单细胞结合特异性。 例如，本发明的MSNP和原细胞可以用于靶向治疗剂到癌细胞或特定血管类型（例如在动脉，静脉和/或毛细血管或血管的任何组合中）的特异性递送。 还提供了相关的原细胞，药物组合物和治疗和诊断方法。
-
Search Results
2
records
(took 0.022 seconds)
